Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy
Background and aims: The regression of liver fibrosis and portal hypertension (PH) and their influence on the natural history of compensated hepatitis C virus (HCV)-related cirrhosis has not been studied previously. Our objective was to evaluate the influence of sustained virologic response (SVR) on the portal pressure gradient (HVPG) and non-invasive parameters of PH and prognostic factors of response. Methods: Sixteen patients with compensated HCV genotype 1-related cirrhosis with PH (HVPG > 6 mmHg) without beta-blocker therapy were considered as candidates for PEGα2a + RBV + BOC (48 weeks; lead-in and accepted stopping rules). A hemodynamic study and Fibroscan® were performed at baseline, at eight weeks and, in the case of SVR, 24 weeks after treatment. In each hemodynamic study, serum samples were analyzed for inflammatory biomarkers associated with PH. Results: In eight cases, SVR was obtained; five patients relapsed, and treatment was stopped early for non-response to lead in (one case) and a decrease of < 3 log at week 8 (two patients). Compared to baseline, there was a significant decrease in HVPG and Fibroscan® at weeks 8 and 72 (10.31 ± 4.3 vs 9.4 ± 5.04 vs 6.1 ± 3.61 mmHg, p < 0.0001 and 21.3 ± 14.5 vs 16.2 ± 9.5 vs 6.4 ± 4.5 kPa, p < 0.0001, respectively). The average HVPG decrease in SVR was 40.8 ± 17.53%, achieving an HVPG < 6 mmHg in five patients (62.5%) and a Fibroscan® < 7.1 kPa in three patients (37.5%). Conclusions: Complete hemodynamic response (HVPG < 6 mmHg) and fibrosis regression (Fibroscan® < 7.1 kPa) occur in more than half and one-third of patients achieving SVR, respectively, and must be another target in cirrhotic patients with SVR.
Main Authors: | , , , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedad Española de Patología Digestiva
2017
|
Online Access: | http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082017000100004 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S1130-01082017000100004 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S1130-010820170001000042017-05-29Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapyPuente,ÁngelaCabezas,JoaquínLópez Arias,María JesúsFortea,José IgnacioArias,María TeresaEstébanez,ÁngelCasafont,FernandoFábrega,EmilioCrespo,Javier Portal pressure gradient Portal hypertension Triple therapy SVR Fibroscan® Background and aims: The regression of liver fibrosis and portal hypertension (PH) and their influence on the natural history of compensated hepatitis C virus (HCV)-related cirrhosis has not been studied previously. Our objective was to evaluate the influence of sustained virologic response (SVR) on the portal pressure gradient (HVPG) and non-invasive parameters of PH and prognostic factors of response. Methods: Sixteen patients with compensated HCV genotype 1-related cirrhosis with PH (HVPG > 6 mmHg) without beta-blocker therapy were considered as candidates for PEGα2a + RBV + BOC (48 weeks; lead-in and accepted stopping rules). A hemodynamic study and Fibroscan® were performed at baseline, at eight weeks and, in the case of SVR, 24 weeks after treatment. In each hemodynamic study, serum samples were analyzed for inflammatory biomarkers associated with PH. Results: In eight cases, SVR was obtained; five patients relapsed, and treatment was stopped early for non-response to lead in (one case) and a decrease of < 3 log at week 8 (two patients). Compared to baseline, there was a significant decrease in HVPG and Fibroscan® at weeks 8 and 72 (10.31 ± 4.3 vs 9.4 ± 5.04 vs 6.1 ± 3.61 mmHg, p < 0.0001 and 21.3 ± 14.5 vs 16.2 ± 9.5 vs 6.4 ± 4.5 kPa, p < 0.0001, respectively). The average HVPG decrease in SVR was 40.8 ± 17.53%, achieving an HVPG < 6 mmHg in five patients (62.5%) and a Fibroscan® < 7.1 kPa in three patients (37.5%). Conclusions: Complete hemodynamic response (HVPG < 6 mmHg) and fibrosis regression (Fibroscan® < 7.1 kPa) occur in more than half and one-third of patients achieving SVR, respectively, and must be another target in cirrhotic patients with SVR.Sociedad Española de Patología DigestivaRevista Española de Enfermedades Digestivas v.109 n.1 20172017-01-01journal articletext/htmlhttp://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082017000100004en |
institution |
SCIELO |
collection |
OJS |
country |
España |
countrycode |
ES |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-es |
tag |
revista |
region |
Europa del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Puente,Ángela Cabezas,Joaquín López Arias,María Jesús Fortea,José Ignacio Arias,María Teresa Estébanez,Ángel Casafont,Fernando Fábrega,Emilio Crespo,Javier |
spellingShingle |
Puente,Ángela Cabezas,Joaquín López Arias,María Jesús Fortea,José Ignacio Arias,María Teresa Estébanez,Ángel Casafont,Fernando Fábrega,Emilio Crespo,Javier Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy |
author_facet |
Puente,Ángela Cabezas,Joaquín López Arias,María Jesús Fortea,José Ignacio Arias,María Teresa Estébanez,Ángel Casafont,Fernando Fábrega,Emilio Crespo,Javier |
author_sort |
Puente,Ángela |
title |
Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy |
title_short |
Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy |
title_full |
Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy |
title_fullStr |
Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy |
title_full_unstemmed |
Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy |
title_sort |
influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic hcv patients treated with antiviral triple therapy |
description |
Background and aims: The regression of liver fibrosis and portal hypertension (PH) and their influence on the natural history of compensated hepatitis C virus (HCV)-related cirrhosis has not been studied previously. Our objective was to evaluate the influence of sustained virologic response (SVR) on the portal pressure gradient (HVPG) and non-invasive parameters of PH and prognostic factors of response. Methods: Sixteen patients with compensated HCV genotype 1-related cirrhosis with PH (HVPG > 6 mmHg) without beta-blocker therapy were considered as candidates for PEGα2a + RBV + BOC (48 weeks; lead-in and accepted stopping rules). A hemodynamic study and Fibroscan® were performed at baseline, at eight weeks and, in the case of SVR, 24 weeks after treatment. In each hemodynamic study, serum samples were analyzed for inflammatory biomarkers associated with PH. Results: In eight cases, SVR was obtained; five patients relapsed, and treatment was stopped early for non-response to lead in (one case) and a decrease of < 3 log at week 8 (two patients). Compared to baseline, there was a significant decrease in HVPG and Fibroscan® at weeks 8 and 72 (10.31 ± 4.3 vs 9.4 ± 5.04 vs 6.1 ± 3.61 mmHg, p < 0.0001 and 21.3 ± 14.5 vs 16.2 ± 9.5 vs 6.4 ± 4.5 kPa, p < 0.0001, respectively). The average HVPG decrease in SVR was 40.8 ± 17.53%, achieving an HVPG < 6 mmHg in five patients (62.5%) and a Fibroscan® < 7.1 kPa in three patients (37.5%). Conclusions: Complete hemodynamic response (HVPG < 6 mmHg) and fibrosis regression (Fibroscan® < 7.1 kPa) occur in more than half and one-third of patients achieving SVR, respectively, and must be another target in cirrhotic patients with SVR. |
publisher |
Sociedad Española de Patología Digestiva |
publishDate |
2017 |
url |
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082017000100004 |
work_keys_str_mv |
AT puenteangela influenceofsustainedviralresponseontheregressionoffibrosisandportalhypertensionincirrhotichcvpatientstreatedwithantiviraltripletherapy AT cabezasjoaquin influenceofsustainedviralresponseontheregressionoffibrosisandportalhypertensionincirrhotichcvpatientstreatedwithantiviraltripletherapy AT lopezariasmariajesus influenceofsustainedviralresponseontheregressionoffibrosisandportalhypertensionincirrhotichcvpatientstreatedwithantiviraltripletherapy AT forteajoseignacio influenceofsustainedviralresponseontheregressionoffibrosisandportalhypertensionincirrhotichcvpatientstreatedwithantiviraltripletherapy AT ariasmariateresa influenceofsustainedviralresponseontheregressionoffibrosisandportalhypertensionincirrhotichcvpatientstreatedwithantiviraltripletherapy AT estebanezangel influenceofsustainedviralresponseontheregressionoffibrosisandportalhypertensionincirrhotichcvpatientstreatedwithantiviraltripletherapy AT casafontfernando influenceofsustainedviralresponseontheregressionoffibrosisandportalhypertensionincirrhotichcvpatientstreatedwithantiviraltripletherapy AT fabregaemilio influenceofsustainedviralresponseontheregressionoffibrosisandportalhypertensionincirrhotichcvpatientstreatedwithantiviraltripletherapy AT crespojavier influenceofsustainedviralresponseontheregressionoffibrosisandportalhypertensionincirrhotichcvpatientstreatedwithantiviraltripletherapy |
_version_ |
1755938733710901248 |